{"product_id":"overcoming-steroid-insensitivity-in-respiratory-disease-isbn-9780470058084","title":"Overcoming Steroid Insensitivity in Respiratory Disease","description":"Written by well-known experts in field, this is the first book dedicated to dealing with the single most challenging management issue in long-term steroid therapy.  \u003cp\u003e\u003cb\u003e\u003ci\u003eOvercoming Steroid Insensitivity in Respiratory Disease\u003c\/i\u003e\u003c\/b\u003e reviews important new advances in therapeutics and provides the clinician with the most up to date information on one of the most significant therapeutic challenges to effective management of these diseases. This unique book is an invaluable resource for all postgraduate students and specialist physicians in pulmonology allergy and asthma. It is also of interest for workers in biomedical and pharmaceutical research.\u003c\/p\u003e  \u003cb\u003eContents\u003c\/b\u003e  \u003cp\u003e\u003cb\u003eList of contributors\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePreface\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Molecular Mechanisms of Glucocorticoid Receptor Action\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003ePankaj Bhavsar and Ian M. Adcock\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1.1 Introduction\u003c\/p\u003e \u003cp\u003e1.2 Glucocorticoid receptor\u003c\/p\u003e \u003cp\u003e1.3 Gene induction by GR\u003c\/p\u003e \u003cp\u003e1.4 GR transactivation and histone acetylation\u003c\/p\u003e \u003cp\u003e1.5 Post-translational modifications of GR\u003c\/p\u003e \u003cp\u003e1.6 Repression of NF-êB-induced inflammatory gene expression by GR–NF-êB\u003c\/p\u003e \u003cp\u003e1.7 GR–NF-êB cross-talk\u003c\/p\u003e \u003cp\u003e1.8 Role of HDAC2 in glucocorticoid function\u003c\/p\u003e \u003cp\u003e1.9 Overexpression of HDAC2 restores glucocorticoid sensitivity in alveolar macrophages\u003c\/p\u003e \u003cp\u003e1.10 Acetylation of hsp90 and regulation of GR function\u003c\/p\u003e \u003cp\u003e1.11 Other mechanisms of GR action\u003c\/p\u003e \u003cp\u003e1.12 Conclusions\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Side Effects of Topical and Oral Glucocorticoids\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eHeike Schäcke, Khusru Asadullah and Wolf-Dietrich Döcke\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.1 Introduction\u003c\/p\u003e \u003cp\u003e2.2 Glucocorticoid-induced side effects\u003c\/p\u003e \u003cp\u003e2.3 Summary\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Glucocorticoid Receptor Subtypes and Steroid Sensitivity\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eRobert H. Oakley and John A. Cidlowski\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.1 Introduction\u003c\/p\u003e \u003cp\u003e3.2 Overview of classic GR function\u003c\/p\u003e \u003cp\u003e3.3 GR subtypes arising from alternative splicing\u003c\/p\u003e \u003cp\u003e3.4 GR subtypes arising from alternative translation initiation\u003c\/p\u003e \u003cp\u003e3.5 Conclusions\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Dissociated Glucocorticoids\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eIan M. Adcock\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.1 Introduction\u003c\/p\u003e \u003cp\u003e4.2 Asthma and chronic obstructive pulmonary disease are chronic inflammatory diseases of the airways\u003c\/p\u003e \u003cp\u003e4.3 Regulation of inflammatory gene expression\u003c\/p\u003e \u003cp\u003e4.4 Effects on inflammation\u003c\/p\u003e \u003cp\u003e4.5 Mechanisms of glucocorticoid action\u003c\/p\u003e \u003cp\u003e4.6 Dissociated glucocorticoids\u003c\/p\u003e \u003cp\u003e4.7 GR cross-talk with other nuclear receptors and coactivators\u003c\/p\u003e \u003cp\u003e4.8 Overcoming steroid insensitivity\u003c\/p\u003e \u003cp\u003e4.9 Glucorticoid-sparing approaches to anti-inflammatory therapy \u003c\/p\u003e \u003cp\u003e4.10 Conclusion\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Generalized Glucocorticoid Insensitivity: Clinical Phenotype and Molecular Mechanisms\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eEvangelia Charmandari, Tomoshige Kino and George P. Chrousos\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5.1 Introduction\u003c\/p\u003e \u003cp\u003e5.2 Molecular mechanisms of glucocorticoid resistance \u003c\/p\u003e \u003cp\u003e5.3 Conclusions\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Corticosteroid Responsiveness in Asthma: Clinical Aspects\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eKian Fan Chung\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.1 Introduction\u003c\/p\u003e \u003cp\u003e6.2 Effects of corticosteroids in asthma\u003c\/p\u003e \u003cp\u003e6.3 Definition of corticosteroid insensitivity\u003c\/p\u003e \u003cp\u003e6.4 Oral CS responsiveness in asthma\u003c\/p\u003e \u003cp\u003e6.5 ICS responsiveness in asthma\u003c\/p\u003e \u003cp\u003e6.6 CS responsiveness in severe asthma\u003c\/p\u003e \u003cp\u003e6.7 Surrogates for CS responsiveness in asthma\u003c\/p\u003e \u003cp\u003e6.8 Pharmacokinetics of systemic CS in severe asthma \u003c\/p\u003e \u003cp\u003e6.9 CS responsiveness in cigarette smokers and chronic obstructive pulmonary disease\u003c\/p\u003e \u003cp\u003e6.10 Other diseases of CS insensitivity\u003c\/p\u003e \u003cp\u003e6.11 Conclusions\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Glucocorticoid-insensitive Asthma: Molecular Mechanisms\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eJohn W. Bloom\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7.1 Introduction\u003c\/p\u003e \u003cp\u003e7.2 GR abnormalities\u003c\/p\u003e \u003cp\u003e7.3 GR nuclear translocation\u003c\/p\u003e \u003cp\u003e7.4 Cross-talk with transcription factors\u003c\/p\u003e \u003cp\u003e7.5 NF-kB, GR, histones and chromatin remodelling \u003c\/p\u003e \u003cp\u003e7.6 Epigenetics and asthma\u003c\/p\u003e \u003cp\u003e7.7 Conclusions\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Cigarette Smoke, Oxidative Stress and Corticosteroid Responsiveness\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eIrfan Rahman and David Adenuga\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.1 Oxidative stress\u003c\/p\u003e \u003cp\u003e8.2 Cigarette smoke\/oxidative stress-induced NF-kB-mediated pro-inflammatory gene expression\u003c\/p\u003e \u003cp\u003e8.3 Histone acetylation and deacetylation\u003c\/p\u003e \u003cp\u003e8.4 Corticosteroids\u003c\/p\u003e \u003cp\u003e8.5 Histone deacetylases\u003c\/p\u003e \u003cp\u003e8.6 Reversing Glucocorticoids \/ Corticosteroid resistance\u003c\/p\u003e \u003cp\u003e8.7 Conclusion\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Regulation of Glucocorticoid Sensitivity by Macrophage Migration Inhibitory Factor\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eEric F. Morand\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9.1 Introduction\u003c\/p\u003e \u003cp\u003e9.2 MIF as a pro-inflammatory factor\u003c\/p\u003e \u003cp\u003e9.3 Relationship between MIF and glucocorticoids \u003c\/p\u003e \u003cp\u003e9.4 Conclusions\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Steroid-sparing Strategies: Long-acting Inhaled\u003c\/b\u003e \u003cb\u003eβ\u003c\/b\u003e\u003cb\u003e2\u003c\/b\u003e \u003cb\u003e-Agonists\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eAnna Miller-Larsson and Olof Selroos\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10.1 Introduction\u003c\/p\u003e \u003cp\u003e10.2 Why and when is a steroid-sparing effect of LABA important in asthma?\u003c\/p\u003e \u003cp\u003e10.3 Effects of lower dose ICS\/LABA versus a higher dose ICS on lung function, symptoms and use of reliever medication\u003c\/p\u003e \u003cp\u003e10.4 Effects of lower dose ICS\/LABA versus higher dose ICS on exacerbations\u003c\/p\u003e \u003cp\u003e10.5 Protocols with tapering ICS doses with and without LABA while maintaining asthma control\u003c\/p\u003e \u003cp\u003e10.6 Reducing ICS doses using an adjustable ICS\/LABA dosing regimen\u003c\/p\u003e \u003cp\u003e10.7 Reducing ICS doses using Symbicort® maintenance and reliever therapy\u003c\/p\u003e \u003cp\u003e10.8 Does enhanced anti-inflammatory efficacy explain steroid-sparing effects in ICS\/LABA therapy?\u003c\/p\u003e \u003cp\u003e10.9 Possible Mechanisms of Steroid-sparing Effects by Addition of LABA to ICS\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Steroid-sparing Strategies: Other Combinations\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eGaetano Caramori, Kazuhiro Ito and Alberto Papi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11.1 Introduction\u003c\/p\u003e \u003cp\u003e11.2 Theophylline as steroid-sparing treatment in asthma and COPD\u003c\/p\u003e \u003cp\u003e11.3 Selective inhibitors of PDE4\u003c\/p\u003e \u003cp\u003e11.4 Modulators of the synthesis or action of key inflammatory mediators\u003c\/p\u003e \u003cp\u003e11.5 Anticholinergics\u003c\/p\u003e \u003cp\u003e11.6 Leukotriene synthesis inhibitors and leukotriene receptor antagonists\u003c\/p\u003e \u003cp\u003e11.7 Anti-lgE therapy\u003c\/p\u003e \u003cp\u003e11.8 Macrolides\/ketolides\u003c\/p\u003e \u003cp\u003e11.9 TNFá inhibitors\u003c\/p\u003e \u003cp\u003e11.10 Conclusions\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Kinases as Anti-inflammatory Targets for Respiratory Disease\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eIain Kilty\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12.1 Introduction\u003c\/p\u003e \u003cp\u003e12.2 Pharmacological targeting of kinases\u003c\/p\u003e \u003cp\u003e12.3 Targeting NF-êB activation \u003c\/p\u003e \u003cp\u003e12.4 Targeting the MAPKs\u003c\/p\u003e \u003cp\u003e12.5 Targeting PI3K\u003c\/p\u003e \u003cp\u003e12.6 Further potential kinase targets\u003c\/p\u003e \u003cp\u003e12.7 Conclusions\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Pharmacokinetic\/Pharmacodynamic Factors and Steroid Sensitivity\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eGönther Hochhaus\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13.1 Introduction\u003c\/p\u003e \u003cp\u003e13.2 What factors are important for pulmonary efficacy and safety?\u003c\/p\u003e \u003cp\u003e13.3 Pharmacodynamic aspects\u003c\/p\u003e \u003cp\u003e13.4 Pharmacokinetic drug properties\u003c\/p\u003e \u003cp\u003e13.5 Conclusion\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Improved Lung Deposition: New Inhaler Devices\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eOmar S. Usmani\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14.1 Introduction\u003c\/p\u003e \u003cp\u003e14.2 Historical review of inhaled drug therapy\u003c\/p\u003e \u003cp\u003e14.3 Deposition of aerosols within the respiratory tract\u003c\/p\u003e \u003cp\u003e14.4 Assessing drug deposition in the lungs\u003c\/p\u003e \u003cp\u003e14.5 Aerosol generation devices for inhaled drug therapy\u003c\/p\u003e \u003cp\u003e\u003cb\u003eIndex\u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e\u003cstrong\u003eIan Adcock\u003c\/strong\u003e, Professor of Respiratory Cell and Molecular Biology at the National Heart and Lung Institute, Royal Brompton Campus,?London, UK. \u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eK Fan Chung\u003c\/strong\u003e, Professor, Experimental Studies Group, NHLI, Royal Brompton Campus,?London, UK.   Since their discovery in the 1950's, the therapeutic use of corticosteroids has been the mainstay of treatment for many chronic inflammatory diseases. Their utility has been tempered, however, by the increasing risk of side effects with higher dose therapy.  \u003c\/p\u003e\u003cp\u003eIn the treatment of airways diseases, side-effects can be limited by targeted delivery to the airway and lung, and significant progress has been made through the use of increasingly selective molecules, and through a variety of lung targeting strategies. Moreover, the recent developments in our understanding of the molecular and structural mechanisms of action of corticosteroid actions have suggested that it may be possible to develop new corticosteroids with intrinsically different pharmacology.\u003c\/p\u003e \u003cp\u003eA combination of these developments will enable the design of agents with an enhanced therapeutic index and this book, aimed at specialists in pulmonology, provides the clinician who prescribes corticosteroid therapies with the most up-to-date information on one of the most significant therapeutic challenges to effective management of chronic inflammatory diseases.\u003c\/p\u003e \u003cul\u003e \u003cli\u003eFirst book dedicated specifically to this major management issue for respiratory and general physicians.\u003cbr\u003e \u003c\/li\u003e \u003cli\u003eAuthors well-known experts in field.\u003cbr\u003e \u003c\/li\u003e \u003cli\u003eReviews important new advances in therapeutics.\u003c\/li\u003e \u003c\/ul\u003e","brand":"Wiley","offers":[{"title":"Default Title","offer_id":47989744206053,"sku":"NP9780470058084","price":185.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9780470058084.jpg?v=1761785322","url":"https:\/\/k12savings.com\/products\/overcoming-steroid-insensitivity-in-respiratory-disease-isbn-9780470058084","provider":"K12savings","version":"1.0","type":"link"}